HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conflict Of Interest Reform Fight Reignites Following Panel Revelations

This article was originally published in The Tan Sheet

Executive Summary

Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.

You may also be interested in...



FDA Advisory Committees Would Get Patient Influence Under Hagan Bill

Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.

In-Person US FDA Meetings Returning? Agency Will Support Those Events At HQ

A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.

After ‘Clean’ User Fee Renewal, Will Programs Held Hostage Be Enough To Drive A Broader Reform Bill?

Continuing resolution will force lawmakers back to the bargaining table before year end. Orphan grants and pediatric exclusivity are among the programs left out of the short-term spending measure as Congressional Democrats seek leverage to add more policy riders.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel